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Abstract
Here we investigate the effects of expressing an activated mutant of Notch (ICD-E) in an inducible transgenic mouse model.
Hepatic expression of ICD-E in adult animals has no detectable phenotype, but simultaneous induction of ICD-E in both the
liver and small intestine results in hepatic steatosis, lipogranuloma formation and mild insulin resistance within 96 hours.
This supports work that suggests that fatty liver disease may result from disruption of the gut-liver axis. In the intestine, ICD-
E expression is known to produce a transient change in the proportion of goblet cells followed by shedding of the
recombinant epithelium. We report additional intestinal transcriptional changes following ICD-E expression, finding
significant transcriptional down-regulation of rpL29 (ribosomal protein L29), which is implicated in the regulation of
intestinal flora. These results provide further evidence of a gut-liver axis in the development of fatty liver disease and insulin
resistance and validate a new model for future studies of hepatic steatosis.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is associated with the
metabolic syndrome, a cluster of factors associated with the
development of insulin resistance and atherosclerosis which has
reached epidemic proportions in the developed world [1]. NAFLD
includes a range of disorders, from simple steatosis which may be
benign to non-alcoholic steatohepatitis (NASH), in which fatty
liver is associated with inflammation [2,3]. Patients with NASH
may in turn develop liver fibrosis which may progress to liver
failure [4,5].
The pathogenesis of NAFLD is complex and multiple processes
are implicated in the accumulation of hepatic lipid. These include
increased levels of plasma free fatty acids, due to increased lipolysis
in adipose tissue or a high fat diet; increased de-novo lipogenesis
within the liver; suppression of Very Low Density Lipoprotein
(VLDL) secretion from the liver and decreased hepatic fatty acid
oxidation [6,7]. These processes may share a final common
pathway in triggering endoplasmic reticulum stress and the
unfolded protein response acting via the transcription factor
XBP1, driving both steatosis and insulin resistance [7].
There is increasing evidence that disruption of the gut-liver axis
may be involved in the pathogenesis of fatty liver disease. Gut
permeability is increased in NAFLD patients and levels of
circulating bacterial derived endotoxin rise in human subjects
placed on a high fat diet [8,9]. In mice, a continuous infusion of
endotoxin results in fatty liver, weight gain, and hepatic insulin
resistance [10]. The microflora of the intestine may also have a
role in NAFLD. Obese humans and mice have a distinctive gut
microflora, which confers obesity when transferred from obese
mice to germ free lean animals [11,12]. Taken together these
results support a role of disruption of the epithelial barrier and/or
intestinal microflora in the development of NAFLD.
In this study we investigate the hepatic phenotype produced by
transgenic activation of Notch signaling in the intestine. Notch
regulates many cell fate decisions in development and in adult life
[13,14]. Signal transduction occurs when the transmembrane
Notch receptor is bound by ligands, such as Jagged, expressed on
adjacent cells [15]. The intracellular domain of the receptor (ICD)
is cleaved from the transmembrane domain by c secretase and
translocates to the nucleus where it binds the transcription factor
CBF1 (RBPJ-K), leading to the recruitment of transcriptional co-
activators and the expression of Notch target genes, such as
members of the hairy-enhancer of split (Hes) family of transcrip-
tion factors [16,17].
Notch signaling plays a key role specifying differentiation in the
intestinal epithelium in developing and adult mice [18,19,20,21].
Previously we have shown that conditional expression of an
activated Notch mutant fused to Enhanced Green Fluorescent
Protein (EGFP) (ICD-E) in the intestine of adult mice results in a
transient increase in goblet cells on the villus, within 24 hours of
Notch activation, followed by crypt apoptosis and shedding of the
recombinant epithelium [20]. This conditional expression system
also results in gene expression in the liver, where Notch has been
shown to regulate bile duct formation in developing and early
post-natal mice [22,23,24,25,26].
Here we report that whereas ICD-E expression in the adult
mouse liver alone has no detectable phenotype, induction of ICD-
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E in the intestine and liver of adult mice results in fatty liver disease
associated with lipogranuloma formation and insulin resistance
within four days. Further, we identify transcripts altered by ICD-E
expression in the intestine, including rpL29 which has a role in
innate immunity. These results provide further support for the role
of the intestine in NAFLD and describe a new model of this
disease.
Results
Transgenic expression of an activated Notch mutant
To investigate the effects of activating Notch signaling in adult
mice we used a constitutively active mutant consisting of the
intracellular domain of Notch1 fused to EGFP (ICD-E). This
mutant localizes to the nucleus and activates transcription of a
Notch responsive reporter over 100 fold when transfected into
hepatocyte derived cell lines (Figure S1 and data not shown). For in
vivo experiments we used a transgenic strain in which ICD-E was
conditionally targeted to the ubiquitously expressed Rosa26 locus
to generate heterozygous R26ICD-E/wt mice, with a loxP flanked
‘‘STOP’’ cassette preventing ICD-E transcription (Figure 1A) [20].
These animals were crossed with the Ahcre transgenic strain to
generate doubly heterozygous Ahcre/R26ICD-E/wt animals. In
these mice cre recombinase, under the control of the Cyp1A1
promoter, is transiently expressed following intraperitoneal
injection of the xenobiotic b–napthoflavone (bNF) [27]. This
results in expression of ICD-E through cre-mediated removal of the
‘‘STOP’’ cassette. As a control we used Ahcre/R26EYFP/wt animals
which are identical to the experimental strain except enhanced
yellow fluorescent protein (EYFP) rather than ICD-E is expressed
from the Rosa26 locus following cre induction: these animals were
treated with the same dose of bNF as experimental animals to
control for the potential effects of transient activation of the Ah
receptor [28,29].
Treatment of the Ahcre strain with high doses of bNF has
previously been shown to induce recombination in the liver and
intestine [27]. We titrated the dose of bNF in Ahcre/R26EYFP/wt
control mice finding that a single dose of 10 mg/kg bNF results in
significant cre-mediated gene expression in the liver with minimal
induction in the small intestine or other organs whilst 3680 mg/
kg doses produce robust EYFP induction in the intestine and liver
(Figure 1B). There was no EYFP induction in brown or white
adipose tissue, pancreas, skeletal muscle, or brain at any dose level
(data not shown).
Transgenic activation of Notch signaling results in fatty
liver within 4 days
Experimental and control mice were treated with a single
10 mg/kg dose of bNF and culled 96 hours later. Histological
examination of the livers of both the experimental and control
animals showed no apparent differences (Figure S2A), despite the
detection of ICD-E and EYFP mRNA and protein by qRT-PCR
and immunostaining respectively (data not shown). There was no
increase in the transcription of Hes1, Sox9 and Hnf1b, all of which
are induced when an activated Notch mutant is expressed in
hepatocytes shortly after birth [22]. In addition there were no
significant differences comparing body weight, liver:body weight
ratio, percentage body fat and insulin tolerance test results in
experimental and control animals (data not shown). Expression of
ICD-E in adult liver alone thus results in no detectable
phenotype.
We therefore investigated the effects of increasing the dose of
bNF to induce gene expression in the liver and small intestine
simultaneously. mRNAs encoding ICD-E or EYFP were readily
detectable in both the liver and in the intestine at 24 hours post-
induction (Figure S2B). In addition, immunohistochemistry
revealed nuclear localized staining in the ICD-E animals and
diffuse cytoplasmic staining in EYFP controls, consistent with in
vitro results (Figure 2A, Figure S1B). Strikingly, small cytoplasmic
vacuoles were visible in hepatocytes in experimental mice at
24 hours post-induction. By 96 hours the experimental livers had
large fat filled vacoules, which was confirmed with the lipid stain
Sudan III (Figure 2B). Areas of leukocytic infiltration consistent
with lipogranuloma formation were also seen (Figure 2C). We
undertook a systematic histological evaluation of the livers,
scoring the severity of steatosis and lipogranuloma formation
[30]. There were statistically significant differences in both
steatosis grade and the occurrence of lipogranuloma in
experimental animals compared with controls at 96 hours post-
induction (p = 0.021 and p= 0.049 respectively by Fisher’s exact
test, Figure 3). Interestingly by 16 days the phenotype has almost
Figure 1. Conditional expression of an activated Notch mutant
(ICD-E) in transgenic mice. A: Experimental strategy. In the R26ICD-E/
ICD-E transgenic strain, cDNA encoding a constitutively active Notch
cytoplasmic domain mutant, fused to EGFP, is targeted to the first
intron of the widely expressed Rosa26 locus. ICD-E expression is
prevented by an upstream ‘STOP’ cassette, flanked by loxP sequences
(triangles), which contains a transcriptional termination sequence. A
splice acceptor (SA) site upstream of the ICD-E cDNA allows normal
processing of the transcript after removal of the ‘STOP’ cassette. R26ICD-
E/ICD-E animals are crossed onto the Ahcre strain, in which expression of
cre recombinase is under the control of the drug inducible CYP1A1
promoter. Following treatment with b-napthoflavone (bNF) the ‘STOP’
cassette is excised through cre-mediated recombination and ICD-E is
expressed [20]. B: bNF dose titration in Ahcre/R26EYFP/wt mice. EYFP
expression levels in each tissue presented as average ratio of each dose
point to un-induced mice +/2 s.e.m. (n = 3/dose point).
doi:10.1371/journal.pone.0020767.g001
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resolved (Figure S3), this suggests that it is of rapid onset but
transient in nature.
Analysis using qRT-PCR showed no difference in key
transcripts from the major pathways implicated in the develop-
ment of NAFLD comparing experimental and control animals
(Table S1) [31,32,33,34,35,36]. To gain further insight into the
pathogenesis of NAFLD in the ICD-E mice we therefore
examined liver transcription at 6 and 24 hour time points, using
expression microarrays. Transcription of two genes involved in
fatty acid uptake were up-regulated at 6 hours post-induction
(Table 1); Abcd2, a gene known to be involved in the peroxisomal
import of fatty acids [37], and the very low density lipoprotein
receptor (Vldlr) [38]. It is also interesting to note that a previous
report has indicated that Abcd2 suppresses transcription of the
fatty acyl chain elongase Elovl3 and this was supported by our data
at all time points [39].
Finally we investigated the expression of known Notch target
genes following ICD-E induction. Cdkn1a, which is directly
regulated by Notch, was up-regulated in the livers of the ICD-E
mice (Table 1) [40]. However hepatic transcription of another
Notch target, the transcription factor Hes1, which has been
implicated in the regulation of hepatic lipid metabolism and fatty
liver disease (FLD), was unchanged (data not shown) [41]. The
levels of mRNAs encoding the Hes1 related genes Hes5, Hey1 and
Hey2 were also unchanged by ICD-E expression, as were Sox9 and
Hnf1b (data not shown) [22,42]. In contrast to the liver, strong
induction of Hes5 follows expression of ICD-E in the intestine [20].
Fatty liver is associated with insulin resistance
Fatty liver is often associated with insulin resistance in the
metabolic syndrome [43]. We therefore investigated animals with
ICD-E driven FLD with an insulin tolerance test performed
72 hours post-induction (Figure 4). The glucose levels were higher
in the ICD-E mice compared to EYFP controls at all time points,
the difference reaching statistical significance at 30 mins post-
injection (p = 0.018, unpaired t-test); indicating the ICD-E mice
have developed mild insulin resistance within a very short time
frame. Haematoxylin and Eosin staining of the pancreas revealed
no morphological changes in the acini or islets of Langerhans (data
not shown).
Figure 2. Hepatic effects of induction of ICD-E in both liver and small intestine. A: Immunohistochemical staining of liver sections from
experimental (ICD-E) and control (EYFP) animals at the time points shown after induction. The anti-GFP antibody used detects both ICD-E and EYFP.
Scale bar: 50 mm. B: H and E sections from time points shown in A. Right hand panels show staining for SudanIII which detects lipid. Scale bar: 50 mm.
C: Two examples of lipogranulomas seen in ICD-E mice 96 hours post-induction. Scale bar (left hand panel): 100 mm. Scale bar (centre and right hand
panel): 50 mm.
doi:10.1371/journal.pone.0020767.g002
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We measured other parameters in order to assess if there
were more extensive changes in metabolism, but found there
were no significant differences in total body weight, liver weight
or fecal fat content between the experimental and control mice.
This suggests that the phenotype was not the result of an
increase in food intake or mal-absorption in the intestine
(Figure S4A–E). There was also no significant difference in the
weight of body fat pads when normalised to body weight
between the ICD-E and EYFP mice (Figure S4F–I), indicating
that substantial mobilisation of fat stores had not occurred
following ICD-E induction. Finally no significant differences
were seen in serum levels of alanine aminotransferase (ALT) or
triglycerides: the levels of cholesterol were higher in the ICD-E
mice but this was not statistically significant (Figure S5). We
concluded that ICD-E induced FLD is unlikely to be due either
to increased dietary fat intake or transportation from peripheral
fat pads.
Next we investigated the intestinal microflora in experi-
mental and control animals. Comparison of gut microflora
between lean C57Bl/6and obese ob/ob mice reveals differences
in the relative abundance of bacterial species, with an increase
in Firmicutes and a decrease in Bacteroidetes [44]. Similar
changes are found comparing obese and lean humans [45]. We
assayed the relative levels of different bacterial species in
induced EYFP and ICD-E mice by qRT-PCR of DNA
extracted from fecal material, but found no significant difference
between the experimental and control animals (Figure S6). We
also attempted to quantify the levels of bacterial endotoxin in
the plasma 24 hours post induction, but there were no apparent
differences between the experimental and control animals (data
not shown).
Transcriptional changes following ICD-E expression in
intestinal epithelium
Expression of ICD-E in the small intestine is required to
trigger fatty liver. To better understand the changes in the
intestinal epithelium induced by ICD-E, we assayed transcrip-
tion in the small intestine by expression microarray analysis at
24 hours post induction of ICD-E or EYFP, as the intestine
contains abundant recombinant epithelium at this time point
[20]. Comparison of experimental and control arrays revealed
significant changes in two transcripts which were validated by
qRT-PCR in samples from an independent experiment. The
first was the mRNA encoding ribosomal protein L29 (rpL29),
also known as heparin/heparan sulfate interacting protein,
which was down-regulated in ICD-E animals at 24 hours post-
induction (Figure 5A). This change could also be shown at the
protein level (Figure 5B). rpL29 expression recovered by
72 hours, coincident with the shedding of ICD-E expressing
cells from the epithelium [20,46]. rpL29 has been shown to be
expressed on the epithelial surface of the small intestine and
exhibits broad antimicrobial activity, suggesting a role in the
innate epithelial defense [47]. We also observed a significant
down-regulation of the abhd1 transcript in the intestine of ICD-E
mice (Figure 5C). Abhd1, a member of the AB hydrolase family,
is expressed in a wide range of tissues and may be involved in
regulation of reactive oxygen species [48]. It is interesting to
note that the expression of this gene is decreased both in the
intestine and the liver, suggesting common regulation following
ICD-E expression in both tissues (Table 1).
Figure 3. Histological grading of liver phenotype. Liver H&E
sections from experimental and control induced mice were graded
according to severity of steatosis (A) and presence or absence of
microgranulomas (B) at 96 hours post induction. Comparison of ICD-E
and EYFP by Fisher exact test *p = 0.021, **p= 0.049. n = 6 for EYFP,
n = 7 for ICD-E.
doi:10.1371/journal.pone.0020767.g003
Table 1. Hepatic transcripts found to be significantly altered
on expression microarray.
Gene
Symbol
Average fold
change
6 h 24 h
Increase
Abcd2 ATP-binding cassette, subfamily3,
member 2
3.46 3.8
ApoA4 Apolipoprotein A4 1.53 3.31
Cdkn1a Cyclin dependent kinase inhibitor 1.03 5.84
Vldlr Very low density lipoprotein receptor 6.16 6.65
Decrease
Ctse Cathepsin E 5.52 69.97
Elovl3 Elongation of very long chain fatty
acids like 3
5.49 3.31
Abhd1 Abhydrolase domain containing 1 39.53 19.26
Table shows microarray transcript fold change in experimental ICD-E mice
relative to control EYFP mice at both 6 and 24 hours post-induction. Data
presented as average fold change (n = 3/genotype/timepoint).
doi:10.1371/journal.pone.0020767.t001
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Discussion
In the present study we demonstrate that over-expression of the
activated mutant of Notch in the liver and small intestine of
transgenic mice, but not in the liver alone, is sufficient to induce a
phenotype that resembles human NAFLD coupled with mild
insulin resistance.
There are a several environmental and genetic models of fatty
liver disease including the ob/ob mouse strain and methionine-
choline deficient diets, however all have the disadvantage of taking
place over long time periods [49,50]. The model we present
develops NAFLD within 96 hours and also demonstrates that
expression of transcripts from the Rosa26 locus can be specifically
targeted to the liver using low doses of bNF with minimal
recombination in other tissues.
Expression of ICD-E in the intestinal epithelium results
in altered epithelial differentiation with an increased propor-
tion of goblet cells on the villi within 24 hours, followed by a
wave of apoptosis of ICD-E expressing cells in intestinal crypts
[20]. The recombinant epithelium on the villus is then lost by
normal cell turnover so that by 4 days the ICD-E expressing
cells have been entirely replaced by wild type epithelium
(Figure 6). These changes are associated with induction of
Hes1 and Hes5, and as shown above, down-regulation of rpL29.
It is possible that the loss of intestinal rpL29 may contribute to
the hepatic phenotype, as the protein has antimicrobial activity
and is involved in the epithelial barrier against microbial
invasion.
These results also illustrate the striking way in which hepatic
Notch phenotypes depend on the developmental stage at which
the mutation is introduced. Notch has long been linked with
intra hepatic bile duct formation. Mice null for Jagged1 and
expressing a hypomorphic allele of Notch2, and animals null
for the Notch target gene Hes1 exhibit a severe paucity of bile
ducts [24,25], arguing Jagged/Notch2/Hes1 signaling is re-
quired for bile duct formation. Conditional deletion studies
using Albumin cre lines have confirmed these findings [26,51].
Expression of an activating Notch1 mutant in developing
hepatocytes results in an increase in the density of bile ducts
[23]. Strikingly, conditional expression of the same mutant in
early post-natal life redirects hepatocytes into the biliary cell
lineage, a fate change accompanied by induction of Hes1, Sox9
and Hnf1b [22]. In contrast, we find no induction of these
transcripts in 16 week old animals and no evidence of a bile
duct phenotype, indicating Notch acts within a developmental
window.
In conclusion, we show that transient, self limiting disruption of
intestinal epithelium by activation of Notch signaling triggers rapid
onset FLD, associated with hepatic induction of Abcd2, and Vldlr,
genes associated with fatty acid uptake, mild insulin resistance and
granuloma formation (Figure 6), but that this phenotype is
significantly improved 16 days post induction (Figure S3). The
development of FLD coincides with the loss of the antimicrobial
protein rpL29 in the intestinal epithelium. These findings provide
further evidence for the potential role of intestinal factors in
triggering FLD.
Materials and Methods
Ethics Statement
All experiments were performed according to UK Government
Home Office guidelines and conducted under project licence 70-
6362, together with justification application Ref: CRL-NSPOR-
REQ-005. The project was ethically reviewed and approved by
Charles River Ethical Review Committee.
Animals
Homozygous mice from the transgenic line Ahcre were crossed
to homozygous R26ICD-E/ICD-E mice to generate heterozygous
Ahcre/R26ICD-E/wt mice or homozygous R26EYFP/EYFP animals to
generate the Ahcre/R26ICD-E/wt control strain [20,27,29]. All
strains were maintained in a C57Bl/6 background. Control and
experimental animals were approximately age matched and
greater than 16 weeks old. Expression of cre recombinase was
induced by intra peritoneal injections of b-naphthoflavone (bNF,
80 mg/kg, Sigma-Aldrich, Dorset, UK) dissolved in corn oil or
DMSO at 8 mg/ml: use of corn oil or DMSO resulted in identical
phenotypes in experimental animals. After induction animals were
housed separately and kept on a 12 hour light/dark cycle and
given ad libitum access to standard chow (VRF1(P), Special Diet
Services, Essex, UK) and water.
Animal health screens
All mice were housed in a single bio-secure isolator unit.
Sentinel animals were regularly culled and serum analysed for
Murine hepatitis virus, Sendai virus, Pneumonia virus of mice,
Mouse minute virus, Theiler’s murine encephalomyelitis (GDVII),
Respiratory enteric orphan virus, Mouse rotavirus, modified
Vaccinia Ankara, mouse polyoma virus, K-virus, Mouse cyto-
megalovirus, Mouse T-lymphotrophic virus, Mouse lymphocytic
choriomeningitis virus, Hantaan virus, Mouse adenovirus and
Ectromelia virus. Microbiology screening by culture was per-
formed for Bordatella Bronchiseptia, Citrobacter rodentium, Corynebacte-
rium Kutscheri, Salmonella Sp., Beta Strep Sp., Streptobacillus moniliformis,
Strep Pneumoniae, P. multocida, and P. pneumotropica. PCR
screening was performed for Cillia associated respiratory bacillus,
Mycoplasma pulmonis, H. hepaticus, H. bilis, and Helicobacter Sp.
Serology and pathological examination was performed for
Tyzzer’s disease. Parasitological tests were conducted for ectopar-
asites, endoparasites, pathogenic protozoa and serology for
E.cuniculi. All of these tests returned negative results.
Insulin tolerance test
The mice were fasted for 4 hours and then injected with
0.75 U/kg Humulin-S (Eli Lilly, Basingstoke, UK). Tail vein
Figure 4. Insulin Tolerance Test at 72 hours post-induction.
Mice were induced to give expression of ICD-E or EYFP in both the liver
and small intestine, and an insulin tolerance test was performed
72 hours post-induction. Experimental mice (white squares, n = 7) and
control mice (grey squares, n = 6). Data is presented as mean +/2 s.e.m.,
*p = 0.018 (unpaired t-test).
doi:10.1371/journal.pone.0020767.g004
Intestinal Activation of Notch Induces Fatty Liver
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20767
blood was collected at 0, 15, 30, 60 and 120 min intervals and
glucose levels measured using an Optimum Xceed monitoring
system (Abbott group, Maidenhead, Berkshire, UK).
Fecal fat analysis
Fecal material was collected daily and snap frozen. Two pellets
per animal were dried to constant weight at 65uC. Fecal fat was
Figure 5. RpL29 and Abhd1 transcript levels are significantly down-regulated in the small intestine post-induction in ICD-E mice. A:
RpL29 transcript levels as assessed by qRT-PCR 24 hour (n = 6/genotype) and 72 hours (n = 9/genotype) post-induction. *p = 0.02, unpaired t-test. B:
Immunofluorescent staining of small intestine from EYFP control (left panel) and ICD-E experimental (middle panel) mice 24 hours post induction.
Sections are stained with rpL29 (red) and dapi nuclear stain (blue). The right hand panel shows no primary antibody control. Scale bar: 20 mm. C:
Abhd1 transcript levels as assessed by qRT-PCR 24 hours post-induction (n = 7/genotype) *p = 0.028, unpaired t-test.
doi:10.1371/journal.pone.0020767.g005
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measured semi-quantitatively by organic extraction with chlor-
oform:methanol:5 M HCl (1:1:2) [52]. Lipids were weighed after
organic extraction and solvent evaporation and normalized to the
amount of fecal material put into the extraction.
Fecal DNA analysis
Fecal DNA was collected from snap frozen feces using a QiAmp
DNA stool kit (Qiagen, Crawley UK) following manufacturer’s
instructions. 1 ml extracted DNAwas used in subsequent qRT-PCRs.
Clinical chemistry
Serum was collected from a terminal bleed and analysed using a
Roche Diagnostics P-Module 800 clinical chemistry analyzer
(Roche, Hertfordshire, UK). Triglyceride, cholesterol and ALT
levels were measured using appropriate kits from Roche. All this
work was carried out by Charles River Laboratories (Edinburgh,
UK).
Bacterial endotoxin quantification
Mice were induced and culled 24 hours later and plasma
prepared from the terminal bleed. Endotoxin levels were
quantified using the LAL gel clot assay (Associates of Cape Cod
Inc., East Falmouth, MA) following the manufacturer’s instruc-
tions.
Histology
H & E sections were scored according to Kleiner et al [30].
Briefly sections were assessed for the degree of steatosis ,5%
parenchymal involvement was rated as 0, 5–33% (1), 34–66% (2)
and .66% (3). Sections were also assessed for the presence (1) or
absence (0) of microgranulomas.
Immunohistochemistry
Antibodies used were anti-GFP (ab290 Abcam, Cambridge,
UK 1:200 dilution). Tissues were immediately removed after
culling, formalin fixed and paraffin embedded. Antigen retrieval
was performed by boiling under pressure in 10 mM sodium
citrate pH 6 for 3 mins. Sections were treated for 30 mins in
0.3% hydrogen peroxidase at room temperature and then
were blocked in 0.25% fish skin gelatin (Sigma-Aldrich) in
16PBS for one hour. Sections were stained at 4uC overnight
and visualised with the poly-HRP anti-rabbit kit (Dako). Sudan
III staining was carried out according to manufacturer’s
instructions (Sigma-Aldrich). All sections were counterstained
with haematoxylin.
Frozen sections were cut and fixed in 4% paraformaldehyde for
5 mins. These were then blocked in 0.25% fish skin gelatin in
16PBS for an hour at room temperature and incubated with
1:100 rpL29 (sc-103166 Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) overnight at 4uC. Sections were then incubated
with 1:500 anti-goat 546 (Invitrogen, Paisley, UK) for one hour at
room temperature and nuclei were stained with Dapi.
RNA extraction
RNA from liver and small intestine was extracted using the
RNEasy columns (Qiagen) including on column DNase digestion
(Qiagen). RNA from muscle was extracted using the same columns
but after homogenization the sample was treated with 10 ml
10 mg/kg proteinase K at 55uC for 10 mins. For adipose tissue
and the hippocampus RNA was extracted using 500 ml Qiazol
(Qiagen) and homogenized using Precellys 24 (1640 seconds
5500 rpm) (Bertin Technologies) and CK14 bead beating tubes
(Cepheid UK Ltd, Stretton, UK). DNA was removed using Dnase
1 (Applied Biosystems, Warrington UK).
qRT-PCR
qRT-PCR was performed using Taqman probes and mastermix
(Applied Biosytems) according to manufacturer’s instructions using
a Rotorgene 3000 (Qiagen). For the primers below SYBRGreen
mastermix (Qiagen) was used
Figure 6. Illustration of changes following induction of ICD-E or EYFP in the liver and small intestine. Adapted from Zecchini et al
(* indicates worked published by Zecchini et al [20]). In the small intestine following induction of ICD-E or EYFP by injection of b-napthoflavone
recombinant epithelium (shown in green) are visible on the villus and crypt at 24 hours post induction. Over time the recombinant epithelium is shed
into the intestinal lumen. In the liver fat vacuoles (shown in yellow) are apparent as early as 24 hours post induction. By 72 hours the experimental
mice show signs of mild insulin resistance. Hepatic and intestinal transcriptional changes are shown below each panel.
doi:10.1371/journal.pone.0020767.g006
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GapdhF 59-cctcgtcccgtagacaaaa-39 Gapdh 59-tggcaacaatctc-
cactttg-39
Abhd1F 59-tactcccaagctccactgct-39 Abhd1R 59-aggaatcccaa-
catgcagac-39
RpL29F 59-tccgatgacatccgtgacta-39 RpL29R 59-tgcatcttctt-
caggccttt-39
Primers used to amplify specific bacterial groups and total
bacterial 18S rRNA were taken from [53]. Standard curves were
generated and the quantity of group-specific bacterial DNA
calculated as a proportion of total bacterial DNA in the sample.
Quantities of bacteria from the Bacteroides/Prevotella group,
Bifidobacterium genus and Lactobacillus/Leuconostoc/Pediococ-
cus group were assessed.
Expression microarray analysis
RNA was extracted and hybridized to an Illumina MouseWG-6
bead array. All labeling, hybridization and analysis on the liver
samples was performed by Expression Analysis Inc (Durham, NC)
(liver samples) or by the pathology department, University of
Cambridge (Cambridge, UK) (SI samples). RNA from livers from
mice induced with bNF dissolved in DMSO was used. To
minimize the false detection rate the liver array was analysed using
PADE analysis (Permutation Analysis for Differential Expression)
analysis as developed by Expression Analysis (http://www.ex
pressionanalysis.com/docs/Illumina_Two_Group_r1.pdf) [54,55].
For the small intestine array samples are compared by the R
package limma and were filtered by an adjusted p-value which is
corrected to take into account a false discovery rate based on the
0.01 p-value detection threshold [56]. All data is MIAME compliant
and has been deposited in ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/); accession numbers E-MTAB-543 (small intestine
array) and E-MTAB-544 (liver array).
Reporter Assays
AML12 and HepA murine hepatocyte derived cell lines
(ATCC, numbers CRL-2254 and CRL-1830 respectively) were
cultured at 37uC and 5% CO2 in DMEM supplemented with 10%
fetal bovine serum [57,58]. EGFP and ICD-E cDNAs were cloned
into pCS2 [20]. The Notch responsive pGa981-6 reporter
plasmid, containing 12 RBP-J binding sites upstream of a minimal
b–globin promoter was a gift from Ursula Juste, Munich [59]. The
renilla luciferase plasmid pRL-TK (Promega) was used as a
transfection efficiency control. Firefly and Renilla luciferase activity
was measured with a Dual luciferase kit (Promega) 24 hours after
transfection in quadruplicate wells. All results were normalised to
Renilla luciferase activity.
Supporting Information
Figure S1 In vitro validation of ICD-E in hepatocyte
derived cells. A: EGFP or ICD-E was cloned into pCS2 and co-
transfected with a Notch responsive firefly luciferase reporter and
a renilla transfection efficiency control plasmid into the AML12
cell line. Mean firefly luciferase activity normalized to renilla
expression, +/2 s.d. from quadruplicate experiments is shown. B:
cDNAs encoding ICD-E or EGFP were cloned into pCS2 and
transfected into the hepatocyte derived AML12 cell line. Note that
cells expressing ICD-E show distinct nuclear staining, whereas
those transfected with EGFP show more diffuse cytoplasmic
staining. Similar results were seen with the HepG2 line (data not
shown).
(TIF)
Figure S2 Persistence of ICD-E and EYFP transcripts
and liver histology at lower bNF doses. A: Liver histology in
experimental and control mice where induction is targeted to the
liver. B: At highest bNF dose level EYFP and ICD-E transcripts
are detectable in the liver and small intestine. White represents
AhcreICD-E/wt and grey represents control animals AhcreEYFP/wt
(n = 3 all time points). Data presented as average +/2 s.e.m.
(TIF)
Figure S3 Liver phenotype development over 16 day
time course. Liver histology in experimental and control
animals after induction of ICD-E or EYFP in the liver and small
intestine. Time points shown are before induction (0 hr), 24 hr,
4days and 16days post induction. n = 3/genotype/timepoint. Scale
bar: 100 mm.
(TIF)
Figure S4 Biospecimen data for ICD-E and EYFP
animals. Animals were induced to express ICD-E or EYFP in
both the liver and small intestine. In all graphs white represents
AhcreICD-E/wt (n = 7) and grey represents control animals Ah-
creEYFP/wt (n = 6). There were no significant differences in any of
the parameters studied. Mice were weighed daily and weight
normalised to starting weight (A). Feccal pellets were collected
daily and weighed (B) and data is presented as average +/2 s.d. of
each genotype/day. Food intake was also measured daily and is
presented as the average over the whole study course (C). Fat was
extracted from feccal pellets from 2 different days and quantified.
Data presented as mg fat/mg feccal material (n = 3) (D). 72 hours
post-induction animals were culled and the liver and all fat pads
removed and weighed. Tissue weight is presented as a percentage
of body weight. Liver weight (E), retroperitoneal fat pad weight (F),
mesenteric fat pad weight (G), inguinal epididymal fat pad weight
(H), brown fat pad weight (I).
(TIF)
Figure S5 Clinical chemistry data for ICD-E and EYFP
mice. Mice were induced to give expression of ICD-E (white) or
EYFP (grey) in both the liver and small intestine and culled
72 hours later. Serum levels of ALT (A), cholesterol (B) and
triglycerides (C) were quantified (n = 6).
(TIF)
Figure S6 Analysis of fecal DNA. Mice were induced and
fecal pellets collected 72 hours later and DNA extracted. Levels of
specific groups of bacteria (Bacteroides/Prevotella (A), Lactoba-
cillus/Leuconostoc/Pediococcus (B) and Bifidobacterium (C)) as a
proportion of total bacteria DNA, were assessed by qRT-PCR in
ICD-E (white) and EYFP (grey) mice. N=6/genotype.
(TIF)
Table S1 Transcriptional changes in genes implicated in FLD.
Hepatic transcriptional changes in genes associated with main
pathways leading to fatty liver (i.e. increased fatty acid uptake,
increased free fatty acid esterification, increased in de novo
lipogenesis and impaired triglyceride secretion or b-oxidation) at
either 24 hours or 96 hours post-induction. mRNA levels were
quantified by qRT-PCR and normalized to Gapdh, and the ratio
of ICD-E to EYFP calculated. Data presented as average +/2
s.e.m (n= 5/genotype/timepoint, except EYFP 24 hours where
n= 6).
(DOC)
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